Trials by compound
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
The 17 compounds in scope, each with its own page setting out the shape of its indexed record set: how many records, of what class, in what model, over what years, against which endpoints.
Compounds in scope
| Compound | Class | Other names recorded | Index state |
|---|---|---|---|
| Amylin | Amylin and amylin receptor agonists | islet amyloid polypeptide, IAPP | Withheld |
| Cagrilintide | Amylin and amylin receptor agonists, also carried under Incretin receptor agonists | AM833, NNC0174-0833 | Withheld |
| Dulaglutide | Incretin receptor agonists | LY2189265, Trulicity | Withheld |
| Eloralintide | Amylin and amylin receptor agonists | LY3841136 | Withheld |
| Exenatide | Incretin receptor agonists | exendin-4, synthetic exendin-4, Byetta | Withheld |
| GLP-1 | Incretin receptor agonists | glucagon-like peptide-1, GLP-1 (7-36) amide, GLP1 | Withheld |
| Liraglutide | Incretin receptor agonists | NN2211, NNC 90-1170 | Withheld |
| Lixisenatide | Incretin receptor agonists | AVE0010, Adlyxin, Lyxumia | Withheld |
| Maridebart cafraglutide | Incretin receptor agonists | MariTide, AMG 133, AMG133 | Withheld |
| Mazdutide | Incretin receptor agonists | IBI362, LY3305677 | Withheld |
| Orforglipron | Incretin receptor agonists | LY3502970, Foundayo | Withheld |
| Petrelintide | Amylin and amylin receptor agonists | ZP8396 | Withheld |
| Pramlintide | Amylin and amylin receptor agonists | Symlin, pramlintide acetate | Withheld |
| Retatrutide | Incretin receptor agonists | LY3437943 | Withheld |
| Semaglutide | Incretin receptor agonists | NN9535, NNC 0113-0217 | Withheld |
| Survodutide | Incretin receptor agonists | BI 456906 | Withheld |
| Tirzepatide | Incretin receptor agonists | LY3298176, GIP/GLP-1 dual agonist | Withheld |
This index carries names only. Record figures live on the individual pages, which are withheld, so nothing counted there is reproduced here.
Why every page below is withheld
These two classes cover weight-management and metabolic prescribing, which the corpus treats as its highest-risk consumer subject. Every compound here is marked high impact and none has a qualified clinical reviewer recorded, so every page that presents one of their record sets is built, checked and served with a noindex directive and left out of the sitemap.
Nothing is deleted and nothing is softened. The review register sets out the state compound by compound.